Aether Industries Limited – Investor Presentation Summary
Key Operational Highlights
- Q2 FY27 Operating Revenue: ₹3,472 Million, +24% Year-over-Year (YoY)
- H1 FY27 Operating Revenue: ₹6,738 Million
- Business model pivot towards high-margin CRAMS (Contract Research and Manufacturing Services) and CEM (Contract Engineering and Manufacturing) contracts
- Strong traction with customers across different sectors driving performance
Segment-wise Performance
Q2 FY27 Segment Revenue Contribution:
- Oil & Gas: 18.8%
- Pharmaceuticals: 36.6%
- Material Science: 19.4%
- Agrochemicals: 13.3%
- Multiple: 5.6%
- High Performance Photography: 4.2%
- Sustainability & Renewables: 1.1%
- Coatings: 1.0%
H1 FY27 Segment Revenue Contribution:
- Oil & Gas: 18.2%
- Pharmaceuticals: 35.8%
- Material Science: 18.2%
- Agrochemicals: 12.2%
- Multiple: 5.4%
- High Performance Photography: 5.7%
- Sustainability & Renewables: 1.5%
- Coatings: 2.1%
Explanation of significant changes in segment performance: Oil and Gas & Material Science are the main growth drivers despite new product launches in Pharmaceuticals and Agrochemicals. CEM contracts are being negotiated with clients across sectors.
Financial Highlights
Revenue: ₹3,472M (Q2 FY27), ₹6,738M (H1 FY27)
EBITDA: ₹1,104M (Q2 FY27), ₹2,132M (H1 FY27)
PAT: ₹680M (Q2 FY27), ₹1,307M (H1 FY27)
EBITDA Margin: 31.8% (Q2 FY27), 31.6% (H1 FY27)
PAT Margin: 19.6% (Q2 FY27), 19.4% (H1 FY27)
YoY/QoQ comparison: Q2 FY27 PAT increased 26% YoY (from ₹540M in Q2 FY26) and 8.5% QoQ (from ₹627M in Q1 FY27)
Drivers of financial performance: Improved profitability with a shift in segment mix towards higher-margin CRAMS and CEM business models, scale-up of CEM contracts, and pricing benefits.
Key Risks: Not explicitly disclosed in the presentation.
Geographical Revenue Split
Domestic vs Export Revenue (H1 FY27):
- Domestic: 57.6%
- Export: 42.4%
Regional Breakdown: Not specified beyond domestic/export split.
Balance Sheet Snapshot (Consolidated H1 FY27)
Total Assets: ₹36,023M
Total Equity: ₹25,938M
Non-current assets: ₹22,323M
Current assets: ₹13,700M
Non-current liabilities: ₹3,070M
Current liabilities: ₹10,085M
Net Debt: Not explicitly calculated but borrowings visible in liabilities
Reserves: Part of Other Equity (₹24,610M)
Financial Health Insights: Strong asset base growth from ₹31,998M (FY26) to ₹36,023M (H1 FY27), indicating ongoing investments and expansion.
Capex & Cash Flow Health
Capital Expenditure: Evident from Capital work-in-progress of ₹7,052M (H1 FY27) vs ₹5,061M (FY26)
Free Cash Flow: Not explicitly stated
Operating Cash Flow: ₹333M (H1 FY27)
Net Cash Used in Investing Activities: ₹(2,429)M (H1 FY27)
Net Cash from Financing Activities: ₹2,096M (H1 FY27)
Investment Rationale: Focus on capacity expansion with R&D building construction and production block commissioning for pharma LSM, semiconductor, and agrochemicals CEM contracts.
Strategic & R&D Initiatives
Investments in Innovation: ₹406.01M spent on R&D accounting for 6.03% of H1 FY27 revenue
R&D Expansion: 18 fume hoods installed; New R&D Building construction at Catalyst Site-1 expected completion by Q1 FY28
Site Development: Magnum Site-5 - Phase 1: Two production blocks commissioned with pharma LSM product; Equipment installation for two additional blocks for semiconductor and agrochemicals CEM contracts to be commissioned from Q4 FY27 onwards
Expected impact on growth: Strong visibility for fourteen (14) production blocks across sites
Strategic Rationale: Pivot of business model towards CRAMS & CEM contracts to drive higher margins and sustainable growth
Industry Trends & Business Environment
Macro/Industry Trends: Not explicitly discussed in detail
Impact on Company: The company is leveraging sectoral opportunities through negotiated CEM contracts across various industries including pharmaceuticals, agrochemicals, and semiconductors
Management Commentary & Growth Outlook
Strategic Outlook: Business model pivot towards CRAMS and CEM contracts is delivering strong operating income and margin growth
FY Guidance: Not explicitly provided
Market Share Targets: Not specified
Risks and Opportunities: CEM contracts being negotiated with clients across sectors present growth opportunities; Strong visibility for fourteen production blocks indicates robust pipeline